Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

The projected decline in Ipca Laboratories Limited's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.870306
debtToEquity 14.425000
earningsGrowth 0.236000
revenueGrowth 0.066000
grossMargins 0.669450
operatingMargins 0.177960
trailingEps 35.810000
forwardEps 53.955470

IPCALAB's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
IPCALAB's low Debt-to-Equity ratio reflects the company's conservative use of debt. This shows that it isn't over-leveraged, reducing financial risk and indicating a stable financial structure, which is a positive signal for investors concerned about excessive debt burdens.
IPCALAB's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that IPCALAB is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Price projections for IPCALAB have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for IPCALAB's growth and market performance.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


Ipca Laboratories Limited saw 2 transactions in which shares were sold with market price at 1456.75.No sell transactions occurred during the period under consideration.Investors are purchasing IPCALAB more frequently than selling it near the current price levels, which might point to a bullish sentiment. This pattern could be interpreted as a favorable outlook for the stock's future.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Recent analysis shows a strong buy bias for IPCALAB, encouraging investors to view it as a solid investment option. The positive sentiment surrounding IPCALAB suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.